UK’s AstraZeneca says buying US biotech firm Alexion for $39 billion | World News - Hindustan Times
close_game
close_game

UK’s AstraZeneca says buying US biotech firm Alexion for $39 billion

London | ByAgence France-Presse | Posted by Prashasti Singh
Dec 13, 2020 06:04 AM IST

“Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” AstraZeneca chief executive Pascal Soriot said in a statement, announcing the year’s biggest deal in the pharma sector.

British pharmaceuticals group AstraZeneca, which is finalising a vaccine against Covid-19, said Saturday it was buying US biotech firm Alexion for $39 billion to boost its work on immunology.

Both boards have agreed to the cash-and-stock deal, which values Alexion at $175 a share, a premium of 45 percent to the Boston-based company’s closing price on Friday.(REUTERS)
Both boards have agreed to the cash-and-stock deal, which values Alexion at $175 a share, a premium of 45 percent to the Boston-based company’s closing price on Friday.(REUTERS)

“Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” AstraZeneca chief executive Pascal Soriot said in a statement, announcing the year’s biggest deal in the pharma sector.

Experience Delhi’s rich history through a series of heritage walks with HT! Participate Now

Also Read: Oxford-AstraZeneca’s Covid-19 vaccine can be available in 1st half of next year, says official

“We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients,” he said.

Both boards have agreed to the cash-and-stock deal, which values Alexion at $175 a share, a premium of 45 percent to the Boston-based company’s closing price on Friday.

Since taking the helm at AstraZeneca in 2012, Soriot has pushed the group into lucrative treatments such as cancer therapies, and the Alexion takeover will give it more heft in areas such as treating blood disorders.

Along with researchers from the University of Oxford, AstraZeneca has developed an effective Covid-19 vaccine which the UK government plans to use as the lynchpin of its inoculation drive, after first rolling out another vaccine by Pfizer/BioNTech.

Also Read: US should not wait too long on AstraZeneca vaccine, Oxford’s Hill says

But approval of the AstraZeneca/Oxford drug has been held up after queries over its initial trial results.

On Tuesday, the UK partners became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle.

The new acquisition is expected to close in the third quarter of 2021, and Alexion shareholders will own 15 percent of the combined company.

“This transaction marks the start of an exciting new chapter for Alexion,” Alexion chief executive Ludwig Hantson said.

“We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics,” he said.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now! Get Latest World News,RBI MPC Meet 2024 Livealong with Latest News from India at Hindustan Times.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Sunday, February 11, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On